Screener
Summit Therapeutics SMMT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities and sales of short-term investments | 177,293 | 160,532 |
| Purchase of short-term investments | (177,286) | — |
| Purchases of property and equipment | (245) | (422) |
| Net cash (used in) provided by investing activities | (238) | 160,110 |
| Cash flows from financing activities: | ||
| Proceeds received related to employee stock purchase plan and exercise of stock options | 3,797 | 2,019 |
| Proceeds from exercise of warrants (3) | — | 5,658 |
| Net cash provided by financing activities | 3,797 | 7,677 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's investing cash flow?
- Summit Therapeutics (SMMT) reported investing cash flow of -$238K in Q1 2026.
- How has Summit Therapeutics's investing cash flow changed year-over-year?
- Summit Therapeutics's investing cash flow decreased by 100.1% year-over-year, from $160.11M to -$238K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Summit Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude